INSUBCONTINENT EXCLUSIVE:
Flagship Pioneering, the Boston-based biotech incubator and holding company, said it has raised $1.1 billion for its Flagship Labs
unit.Flagship, which raised $1 billion back in 2019 for growth-stage investment vehicles, develops and operates startups that leverage
the strong support of our existing Limited Partners, as well as the interest from a select group of new Limited Partners, to support
chief executive of Flagship Pioneering, in a statement.In addition to its previous focus on health and sustainability, Flagship will use the
Portfolio company Moderna is one of the companies leading efforts to develop a vaccine for the novel coronavirus which causes COVID-19.In
the 20 years since its launch, Flagship has 15 wholly owned companies and another 26 growth-stage companies among its portfolio of
investments.New companies include: Senda Biosciences, Generate Biomedicines, Tessera Therapeutics, Cellarity, Cygnal Therapeutics, Ring
Therapeutics and Integral Health
Growth companies developed or backed by Flagship include Ohana Biosciences, Kintai Therapeutics and Repertoire Immune Medicines.Two of the
companies in the Flagship Labs portfolio have already had initial public offerings in the past two years, the company said
Kaleido Biosciences and Axcella Health raised public capital in 2019, and Moderna Therapeutics conducted a $575 million secondary offering
